The nocebo effect challenges the non-medical infliximab switch in practice

N. W. Boone, L. Liu, M. J. Romberg-Camps, L. Duijsens, C. Houwen, P. H. M. van der Kuy, R. Janknegt, R. Peeters, R. B. M. Landewe, B. Winkens, A. A. van Bodegraven

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)655-661
Number of pages7
JournalEuropean Journal of Clinical Pharmacology
Volume74
Issue number5
DOIs
Publication statusPublished - 1 May 2018

Keywords

  • Inflammatory bowel disease
  • Crohn's disease
  • Ulcerative colitis
  • Rheumatoid arthritis
  • Psoriatic arthritis
  • Ankylosing spondylitis
  • Non-medical switch
  • Nocebo-effect
  • INFLAMMATORY-BOWEL-DISEASE
  • BIOSIMILAR CT-P13
  • ANKYLOSING-SPONDYLITIS
  • ORIGINATOR INFLIXIMAB
  • CLINICAL-OUTCOMES
  • DOUBLE-BLIND
  • ANTIBODIES
  • ARTHRITIS

Cite this

Boone, N. W., Liu, L., Romberg-Camps, M. J., Duijsens, L., Houwen, C., van der Kuy, P. H. M., Janknegt, R., Peeters, R., Landewe, R. B. M., Winkens, B., & van Bodegraven, A. A. (2018). The nocebo effect challenges the non-medical infliximab switch in practice. European Journal of Clinical Pharmacology, 74(5), 655-661. https://doi.org/10.1007/s00228-018-2418-4